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advancement of aeronautics and space science. The
NASA Scientific and Technical Information (STI)
program plays a key part in helping NASA maintain
this important role.
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Results are published in both non-NASA channels
and by NASA in the NASA STI Report Series, which
includes the following report types:
TECHNICAL PUBLICATION. Reports of
completed research or a major significant phase
of research that present the results of NASA
programs and include extensive data or theoretical
analysis. Includes compilations of significant
scientific and technical data and information
deemed to be of continuing reference value.
NASA counterpart of peer-reviewed formal
professional papers but has less stringent
limitations on manuscript length and extent of
graphic presentations.
• TECHNICAL MEMORANDUM. Scientific
and technical findings that are preliminary or
of specialized interest, e.g., quick release
reports, working papers, and bibliographies that
contain minimal annotation. Does not contain
extensive analysis.
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Executive Summary
The changes in the scope of NASA’s mission in the coming decade are profound and demand nimble,
yet insightful, responses. On-board clinical and environmental diagnostics must be available for both mid-
term lunar and long-term Mars exploration missions in an environment marked by scarce resources.
Miniaturization has become an obvious focus. Despite solid achievements in lab-based devices, broad-
based, robust tools for application in the field are not yet on the market.
The confluence of rapid, wide-ranging technology evolution and internal planning needs are the
impetus behind this work. This report presents an analytical tool for the ongoing evaluation of promising
technology platforms based on mission- and application-specific attributes. It is not meant to assess
specific devices, but rather to provide objective guidelines for a rational down-select of general categories
of technology platforms.
In this study, we have employed our expertise in the microgravity operation of fluidic devices,
laboratory diagnostics for space applications, and terrestrial research in biochip development. A rating of
the current state of technology development is presented using the present tool. Two mission scenarios are
also investigated: a 30-day lunar mission using proven, tested technology in 5 years; and a 2- to 3-year
mission to Mars in 10 to 15 years.
For the lunar mission, the key mission requirements are flight readiness and low cost. Our
conclusions are as follows:
Proven dipstick technology is the first choice as a diagnostic tool due to its robustness and ready
availability. However, we note that no commercially available dipstick performs all of the diagnostic
tests required by CHeCS.
If no dipstick exists for a particular desired measurement, the next technology that is most technically
ready is the microfluidic electrochemical sensor. Key concerns are resource requirements,
multidiagnostic capability and field testing.
If electrochemical sensors do not meet the requirement, then antibody-mediated biochips should be
examined. Such technology could provide a definitive measurement due to antibody specificity, but
must be proven in the field before we can recommend them for this application.
For the Mars mission, the decisive mission requirements are long shelf life, adaptability, relative
maturity level, and a confidence level reflecting the surety of obtaining the diagnostic measurement,
through both sensor reliability and backup technology availability. Our findings for this mission scenario
are as follows:
Dipsticks remain the simplest solution, but are typically rated at a 1-year shelf life. If this limitation
can be overcome, e.g., through cryogenic storage, or a combination of cryogenic storage and in-flight
deposition of the reactant, then dipsticks again rise to the top for their robustness and ready
availability.
If dipsticks cannot make the particular measurement, then microscopy techniques have no shelf life
issues, are versatile and provide unique information (e.g., cell pathology). Moreover, they are
technically mature and can be shared among other mission tasks, e.g., investigation of Martian dust.
Issues may remain with biocontainment.
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If microscopy cannot perform the needed diagnostic, then microfluidic electrochemical sensors
should be investigated next. They could be engineered for multidiagnostic measurements in a
resource-efficient manner, but these sensors require some development effort and field testing.
Antibody-mediated biochips could also be multiplexed and represent significant advantages in
providing reliable and specific medical data. Developing this technology class for NASA’s
applications would require more effort, but could provide information that cannot be gleaned from the
above technologies. Shelf life issues must be addressed. Specific devices must be thoroughly tested in
the field before it can be deemed mature enough for long-term, self-sufficient missions.
Nicroarray-based biochips may provide genetic information that is considered crucial in long-term
missions. The devices and their supporting hardware must be made resource-efficient and shelf life
improved. As with the other biochips, field testing is required.
In the next phase of our work, we will apply this methodology to evaluate the technologies against
specific medical requirements, as outlined by the ISS Crew Health Care System (CHeCS).
Background
Biochips, miniaturized sensors, and microfluidic devices represent potential solutions for a range of
on-board clinical and environmental diagnostics. The devices are typically small, lightweight, and low
power (although their supporting hardware may not be similarly resource-efficient). We seek technologies
that can be readily adapted to a broad array of diagnostic tests while remaining faithful to mission
requirements. In particular, we are interested in finding matching technologies for monitoring the
chemical and biochemical composition of the environment, as well as the humans present in that
environment including urinalysis, blood analysis and cell/tissue pathology assays.
A key problem for technology evaluators has been the rapid pace of research and development in the
field, primarily in academic and proprietary labs. NASA and its contractors have also developed or have
been involved with many such devices. However, it is challenging to compare and contrast the features of
such devices, their relative merit with respect to mission needs, and their relative maturity levels based
solely on lab-scale results and technical descriptions.
Moreover, there is a wide gap between the spectrum of potential solutions in the R&D stage and the
few marketed applications today. The presence of such a wide range of specifically targeted devices poses
a range of problems. It is not straightforward to extrapolate data among devices. Different targets may be
used for similar diagnostic information, such as: prothrombin time versus activated partial prothrombin
time; BNP, N-terminal pro-A-type natriuretic peptide, NT-proBNP; intact PHCG versus nicked PHCG,
and other forms of pregnancy hormones; and cardiac biomarkers cTnT versus cTnI. The resulting
measurement can differ in sensitivity and specificity. Even for the same target, results among different
methods or devices are generally not comparable. Other issues arise in the interpretation of results due to
the type of sample (e.g., capillary vs. venous blood), calibration, reference procedures, and the wide
variation in the device interface to external world. The wisest course for NASA missions is to settle on
using specific devices and methods and develop a comprehensive knowledge base in storing, using, and
interpreting the results in the context of spaceflight.
Of course, for any assay, the fundamental measure of utility is the extent to which it informs medical
diagnosis and recommendations. However, concerns such as optimization of system mass, volume, power
requirements for the devices and their consumables, crew time and safety, and waste generation also
become critical in a resource-limited environment. Where possible, we choose least upmass and storage
volume. For example, Roche’s line of Chemstrips dipsticks can be used with a reader for automated
readings of its colorimatric data, but they can also be visually examined without resorting to a separate
reader. For NASA’s purposes, the latter is preferred to reduce resource requirements.
Also, we must predict any issues with fluids handling or other design problems in hardware, operation
and maintenance in a reduced g environment. We also need protocols and hardware for sample collection,
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preprocessing and delivery to the device. Fortunately, there is a rich history of such space system analysis
at NASA, as well as documented flight experience.
Moreover, the rigorous demands of spaceflight subject the devices to an application far outside of the
manufacturers’ development targets. Shelf life, radiation and dust exposure.
This study assumes that NASA will always have a narrow range of targeted applications and an even
narrower budget opportunity. Thus NASA cannot be an innovator, but must rely primarily on well-tested,
available or nearly available technology platforms for its needs. NASA’s unique set of mission
requirements also translates into a different set of selection criteria than those commonly used to evaluate
such technologies for terrestrial applications. NASA must reach a decision point relatively soon for mid-
term exploration initiatives, while recognizing the nature of this moving scientific field. The analysis tool
described here is meant to provide technology analysts and decision-makers with a guide to efficient
allocation of scarce NASA resources for specific missions.
Purpose
The objectives of this study are to:
• Provide an impartial technology assessment of the state-of-the-art and its suitability for specific
exploration missions, independent of the specific state of development of any specific device.
• Develop an analytical tool to evaluate broad categories of technology platforms against mission
requirements, with specific emphasis on biochips.
• Provide a first cut assessment of seven identified key technology platform categories.
• Provide recommendations for early selection of technology platforms for lunar and Mars missions.
• Develop a template for future analyses of new or existing technology platforms.
• Initiate dialog for next steps, including matching NASA and outside available specific devices using
these recommendations.
• Identify gaps, opportunities, and areas for efficient resource allocation.
Technology Assessment
The methodology used to derive the technology assessment tool is based on an objective benefit/risk
assessment, centered on scoring and weighting mission- and performance-related attributes for each
technology platform (columns in Table 1). We defined a few distinct general categories of technology
platforms. Attention is focused on biochip-based technology for medical and environmental diagnostics,
including biochips based on microarrays, electrochemistry, antibody binding, and separations. Other
commonly used medical tests employ ready-to-use lateral flow immunoassays (dipsticks) and various
types of microscopy. We also included a category, “Exotic”, as a catchall for those platforms that may
provide effective solutions but are as yet immature as medical diagnostics for space. Examples of this
category include mass spectrometry and laser light scattering.
We then defined mission and performance attributes, and segregated them into general categories
(rows in Table 1). For clarity, we specified performance targets in column 2 for each attribute, e.g., the
desired target for the power requirement is “low”. The third column labeled “Importance” is assigned a
value from 1 to 5, based on mission parameters. We used literature and web surveys, along with our
understanding of microgravity fluid physics, to assign values from 1 to 5 in the balance of the table for
each combination of attribute and platform. Explanations of each technology platform, category, attribute,
and scoring guidelines are presented in Appendix A. Color saturation based on the assigned value gives a
quick visual display of the leading candidates and potential pitfalls. The procedure resulted in an overall
score for each platform that reflects both the maturity of a given platform and its mission suitability.
Undoubtedly, individual devices will score differently from the values assigned here, which leads to
blurring of the boundaries between technologies. However, we expect that the data will lead to groupings
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of technologies within bands, say those between 4.7 and 5.0. Rather than wading through all possible
devices for each diagnostic test, it would be efficacious to examine the highest-ranking technologies first.
We also note that some technologies may provide absolutely unique information, such as cell
morphology through microscopy, while some diagnostic tests can be obtained in a variety of ways (e.g.,
measurement of cell count through flow cytometry or visual imaging).
Attributes of a technology are classified into five categories. “Medical usefulness” consists of
attributes such as diagnostic value and diagnostic capability. “Astronaut impact” represents traits that
specifically affect the test operator, i.e., the astronaut. This includes operator time and training,
portability, and invasiveness. The latter becomes important in light of the observations of poorer wound
healing in space. Thus, a score of 1 in that attribute denotes a grossly invasive procedure such as excision
of tissue. On the other hand, 5 indicates a test method that is completely external to the astronaut, such as
dipstick testing of urinalysis or infrared determination of glucose concentration in the blood.
TABLE 1.—DIAGNOSTIC ASSESSMENT FOR A LUNAR MISSION WITHIN ABOUT 5 YEARS
Portable Diagnostics Technical Assessment for Space Missions
30-day Lunar Mission within 5 years
Biochips
Desired attributes	 Target Impor= DipsticksMicroscopy Microarray-	 Electro-	 Antibody- Separation- "Exotic" 	 Other
	
tance
	
based
	
chemical I mediated I based
Medical usefulness
	 3
diagnostic value high 5 3 3
2
3
3
3
2
3
3
3
5
2
3
1
1multi-diagnostic capability high 3 4
accuracy high 3 5 2 2 4 4 3 3 1
repeatability high 3 5 2
2
5
4
3
2
4
3
2
3
3
2
2
2
2
3
1
1
1
1
1
validation depth high 4 5
complex media high 2 2
flexibility/adaptability to new uses high 2 1 5
5
1
3
1
3
1
3
4
3
4
1
1
1unique information high 5 2
3.4 1	 3.2 1	 2.8 1	 2.9 1	 2.9 1	 3.0 1	 2.1 1.0
Astronaut impact
	
2
operator time low 4 4 1 2 3 3 2 1 1
operator training low 2 5 1 2 3 3 2 1 1
invasiveness low 5 3 2 3 3 3 3 3 1
portability high 3 5 1 3 3 4 2 1 1
ease of interpretation high 2 5 1	 2 2 1	 2 4 1	 2 1 1
4.1 1	 1.4 1	 2.5 1	 2.9 1	 3.3 1	 2.3 1	 1.6 1	 1.0
Flight constraints	 5
mass low 1	 5 1	 5 1 3 3 3 3 1 1
volume low 5 1 1
3
3
2
4
4
2
3
4
4
2
3
4
4
2
3
3
4
2
3
1
3
1
3
1
1
1
1
consumables low 3 4
power low 5 5
containment high 3 2
shelf life high 4 4 5
5
1	 2
2
3
2
3
3
3
2
3
3
3
3
2
3
3
2
1
1
1
creation of biohazardous waste low 4 3
maintenance low 2 1	 5
3.6 1	 2.7 1	 2.9 1	 3.1 1	 3.0 1	 2.9 1	 2.0 1	 1.0
Technical characteristics
	 3
sensor complexity low 1	 5 5 2 3 3 3 3 1 1
sample preparation low 3 4 1 1 4 3 2 1 1
fluid handling problems in device low 3 5 2 2 2 2 2 1 1
need for supporting equipment low 1 5 3 3 4 3 2 1 1
supporting system complexity low 2 5 2 2 3 3 2 1 1
probable success on earth high 5 5 5 4 5 5 3 4 1
probable success in microgravity high 5 4 4 3 4 4 3 1 1
4.7 3.0 2.8 3.7 3.5 2.6 1.6 1.0
Development issues
	 5
maturity level wrt on-orbit today high 1	 3 5 3 2 2 2 1 1 1
time to TRL7 low 4 5 3 2 4 3 2 2 1
cost to TRL7 low 3 5 3 2 4 3 2 1 1
robustness hi	 h 5 5 2 1 3 3 2 2 1
ease of field testing hlg2 2 5 3 2 4 4 2 1 1
5.0 2.7 1.7 1	 3.4 2.9 1.8 1.5 1.0
SCORE	 4.2	 2.7	 2.5	 3.2	 3.1	 2.5	 1.8	 1.0
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“Flight constraints” are primarily dependent on the use of precious resources, such as mass and power,
and on details associated with extended spaceflight, such as shelf life and maintenance. “Technical
characteristics” assesses the level of simplicity of the diagnostic tool and its supporting hardware, and
fluid handling issues. Finally, “Development issues” incorporates maturity level today, time and cost to
TRL 7, and ease of field testing.
For assessing a longer duration Mars mission, for which more planning time and resources are
available, the scores for each technology remain the same, but the importance changes for attributes and
attribute categories. We assumed that flight constraints are just as important as for the lunar mission, but
the urgency for immediate availability is not as pronounced. We also assumed that astronaut invasiveness
and medical value should increase for a longer term mission.
Recommendations
30-day Lunar Mission in 5 Years
Due to the relatively short time frame and a tight budget, the key requirements for the lunar mission
are flight readiness and low cost. For each required diagnostic test, the top-rated platform(s) should be
investigated first. If no reasonable solution is available in that category of platforms, then the next-rated
platform(s) should be explored, and so on. The results of this assessment show that:
Dipstick-based technology platforms are simple, robust, available, and have high TRL. No
technical issues are foreseen at this time, with the possible exception of biocontainment, but no off-
the-shelf dipstick can perform all of the diagnostics required by the current requirements for the Crew
Health Care System. Some level of development of dipsticks and/or the following platforms are
necessary to meet CHeCS requirements.
Electrochemical biochips are relatively simple and robust, are at relatively high TRL, and are easier
to develop than other biochips. A key concern is the resource requirements of the sensor and its
supporting hardware. Multidiagnostic capability is highly desirable. We believe that field testing is a
crucial component for any such device.
Antibody-mediated biochips are highly versatile, reasonably well-studied, and possess an inherent
richness of possibilities that make it a plausible addition. However, we cannot recommend any device
in this category unless it successfully paasses extensive field testing.
2- to 3-year Mars Mission in 10 to 15 Years
The Mars mission is of much longer duration and must be entirely self-sufficient. Most dipsticks and
antibodies have a rated shelf life on the order of 1 year, which is a reasonable time frame in an earth
environment. In the context of a multiple-year mission to Mars, however, the shelf life of these devices
could be a show-stopper. Longevity testing is needed, including perhaps some novel approach to
extending shelf life, such as cryostorage and in situ deposition of biological substrates. Other key issues
for this type of mission include adaptability, since the desired diagnostics may evolve along with the
mission. If the platform should fail, redundancy, or the ability to make the required measurement with
another available device, should be factored into the measurement strategy. The device should also be at a
relatively mature TRL level in order to meet the demands of the mission. With that said, we recommend
the following:
• Dipsticks remain a top choice due to their simplicity and robustness, if the shelf life issue can be
overcome. At this time, no commercially available dipstick can perform all of the diagnostics required
by CHECS.
• Microscopy is versatile, provides unique information, has no shelf life issues and is mature. It is
limited in the types of information it can generate, but it can perform blood counts, hematocrit (and
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hemoglobin can be derived from that). It can also provide unique information on diagnostics such as
cell pathology. Finally, it can be a shared resource with other mission tasks.
Electrochemical biochips (see above).
Antibody-mediated biochips (see above).
Nicroarray-based biochips may provide genetic information that is considered crucial in long-term
missions. The devices and their supporting hardware must be made resource-efficient and shelf life
improved. As with the other biochips, field testing is required.
How to Use These Recommendations
The above recommendations were reached using the risk/benefit analysis protocol described above.
We selected the attribute list, their relative importance, and other criteria based on our expertise in
spacebound hardware operation and biochip development. Other analysts are invited to modify the
assessment to their understanding and compare to our conclusions.
This study is a technology platform assessment relative to mission-specific issues. It is not meant to
rank or evaluate any specific technology or device. It provides a first cut at an analytical tool for ranking
the suitability of a technology platform before any specific device/application decision is being
contemplated. While the performance for specific devices may cause some blurring of the boundaries
among the general technologies, we suggest that this analysis be used as a starting point for efficient
resource allocation in internal planning.
Using similar methodology, a follow-up study that focuses specifically on CHeCS requirements is in
process.
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Appendix A. Glossary
Diagnostic Technologies
Dipsticks Lateral flow immunoassay
Microscopy Light, fluorescence, confocal or other microscopy. 	 Also flow
cytometry.
Microarray-based biochipgenetics, PCR
Electrochemical chip Detection of ionic species, chemical co
	
ounds
Antibody-mediated biochip Detection based on antibody recognitio
m
nina mikfluidic device
Separation-based biEp Electrophoresis, HPLC, TLC,etc, in a microfluidic device
"Exotic" Mass spectrometry, laser light scatterng, other high-techtechnology that is immature as medical diagnostics for space
Attributes
Attribute	 I Target	 Description	 1	 1	 2	 3	 4	 5
Medical usefulness
diagnostic value high Do results yield a definitive, specific medical diagnosis? Desiredtobe high 	 i.e., target is high)value)
poor (low diagnostic fair good very good best (hi hdi9	 agnostic value)
multi-diagnostic capability high Can this device measure multiiple targets? More functionalityyi
poor (device has no
multi-diagnostic fair good very good best (high multi-diagnosticdetecting many items is preferable. capability) capability)
accuracy highg
Is the result verifiable to within an acceptable margin of error?
Low marginoferror, highaccuracy is preferred. poor (low accuracy fair good very good best (high accuracy)
repeatability high Are repeated measurements of the same quantity equivalent? poor (poor repeatability) fair good very good best (high repeatability)
Is there a significant validationJknowledge database supporting
validation depth high diagnostic interpretation? Larger bodies of knowledge are poor (small database) fair good very good best (large database)
preferred. I
Can this device handle many types of complex media (e.g., blood, poor (one type of best (any type ofcomplexcomplex media high urine, saliva,tissues, gray water, potable water,...) More iis
referred. medium only)
fair good wry good media)
Can the device be adapted on-orbit to detect other targets? If so, poor (device is built fora best (device can be adaptedflexibili	 lade	 bill	 to new usesty	 Pte ty high its flexibility as a	 dynamic assessment tool under unusual or
unexpected conditions is improved. single type of test only)
fair good very good on-orbit to measure new
targets)
Of the technologies listed in this workbook, can the information poor (can be obtained best (can not be obtained
unique information high obtained by this device be obtained through any other diagnostic through other devices fair good very good through other devices listed
technique? If not, its value in obtaining unique information is high. listed here) here)
Astronaut impact
operatortime low Amountof time required on-orbit for sample preparation,
rocessing andanal	 is. Lesstimeis preferable.
poor (requires much
astronauttime) fair good very good
best (requires little or no
astronauttime
Amount of time required to achieve proficiency in sample poor (requires much best (requires little or nooperator training low acquisistion, preparation, processing and analysis. Simpler
systems will, in general, require less training.training)
fair good wry training)
Extent to which astronaut's body must be invaded to yield a
invasiveness low clinically significant sample. Low invasiveness is highly preferable completely external microneedles pinprick venipuncture excision of tissue
due to lower rate of wound healing in space.
Extent to which astronaut can conveniently carry the device on best (sensor and supporting
portability high extra-vehicular or extra-habitat missions for on-the-spot poor (is not portable) fair good very good hardware are handheld or
diagnostics. 	 High portability is desired. better)
easeofreading results high Results that are unambiguous, instantaneous, and easily read poor (not so easy to fair good verygood best (easyto read results)
without supporting equipment are preferred. read)
Flight constraints
mass low Mass of sensor and its infrastructure. Lower is preferred. poor (high mass) fair good very good best (low mass)
volume low Volume of sensor and its infrastructure. Lower is preferred. poor (high volume) fair good very good best (low volume)
consumables low Reagents, storage containers, needles, mixing containers, devicedisposables, cleaning supplies. Lower is preferred
poor (lots of
consumables fair good very good best (few or no consumables)
power low Lower power consumption is preferred. poor (high powerrequired) fair good very
best (low or no power
requirement)
3 levels of containment at all times is desirable; also weighted by
containment high volume of analyte required for testing, with lower volume poor (poor containment) fair good very good best (highly contained)
requirements being better.
Shelf life of reagents and devices in an extraterrestrial
shelf life high environment, with consideration of biological, material and
mechanical wear. This feature will determine mission 6 months 1 year 3 years 5 years indefinitely
appropriateness.
Waste includes leftover bodily fluids, waste fluids, device poor (lots of waste is best (little or no waste iscreation of biohazardous waste low disposables, supportiing disposables (needles, etc.). 	 Minimal generated) fair good wry good generated)
waste creation is preferred.
maintenance low ng, etc. LowNeed for cleaning, calibrating, storing, monitori ,
poor (lots of
maintenance is fair 9ced wry ^^
best (little or no maintenance
maintenance is preferred.
required) is required)
Technical characteristics
sensor complexity low geometric, chemical, mechanical or other complexity poor (very complex
sensor
fair good very good best(very simple sensor)
sample preparation low sample acquisition, mixing, separating, lysing, and introduction todevice
poor (much sample prep
isrequired fair good verygood
best (little or no saple prep
required)m
fluid handling problems in device low potential for issues with clogging, clearng,cleaning,g 	 """
oor (likely to develop
problems) fair 9ced
very ^^ best (unlikelytodevelop
roblems
need for supportingrfi  equipment low requirements fora reader, power, electronics, etc. oor (requires lots of
supporting equipment) fair good very good
(needs no supporting
uipment
supporting system complexity low geometric, chemical, mechanical or other complexity of entiretem
poor (very complex
supporting 	 em fair good wry
best (simple supporting
em
probable success on earth high a measure of the degree of difficulty in producing reliable results poor (^ likelihood of fair good very good best (likely to be successful)
probable success in microgravity high likelihood of issues associated with fluids in space, e.g., bubble poor (low likelihood of fair good very good best (likely to be successful)management, multiphase flow, wetting problems, containment success)
Development issues
poor (substantial best (flight-qualified and
maturity level wrt on-orbit today high readiness for flight development needed
before flight)
fair good rygood tested)
poor (substantial best (technology is at ortime to low cost to become routine for medical diagnostics developmenttime is
needed)
fair good wry good beyond TRL7)
cost to TRL7 low cefitme to become routine for medical diagn 	 w
poor (significant
dlopmentcost iseve fair good wry good best (technology is at orisbeyond Tgy
needed)
robustness high unlikely to break or malfunction during routine use poor (not robust) fair good ve	 od best (robust
ease of field testing high ease of in situ diagnostics poor (diffifield
cult to test in fair good very good best (easy to test in field)
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